A non-Hodgkin lymphoma of T-cell lineage. It includes the T lymphoblastic lymphoma and the mature T- and NK-cell lymphomas. -- 2003
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation surrounding T-cell non-Hodgkin lymphoma is limited primarily due to its relatively low prevalence and the complexity of its clinical presentation. As this condition affects fewer individuals, comprehensive clinical studies have been challenging to conduct. Additionally, the lack of identified genetic factors and systematic characterization of its clinical features contributes to the gaps in available information.
To navigate your care for T-cell non-Hodgkin lymphoma, consider consulting with a hematologist or an oncologist who specializes in lymphomas, particularly those with experience in T-cell malignancies. While no specific patient organizations are identified, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to cutting-edge therapies and contribute to the understanding of this condition.
There are currently three orphan drug designations related to T-cell non-Hodgkin lymphoma, including the FDA-approved drug vorinostat, and two drugs in development: (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride and Tretinoin. Additionally, there are 668 active clinical trials exploring various treatment options and approaches for this condition. For more information, you can search the active trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=T-cell%20non-Hodgkin%20lymphoma.
Actionable guidance for navigating care for T-cell non-Hodgkin lymphoma
To navigate your care for T-cell non-Hodgkin lymphoma, consider consulting with a hematologist or an oncologist who specializes in lymphomas, particularly those with experience in T-cell malignancies. While no specific patient organizations are identified, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to cutting-edge therapies and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding T-cell non-Hodgkin lymphoma is limited primarily due to its relatively low prevalence and the complexity of its clinical presentation. As this condition affects fewer individuals, comprehensive clinical studies have been challenging to conduct. Additionally, the lack of identified genetic factors and systematic characterization of its clinical features contributes to the gaps in available information.
To navigate your care for T-cell non-Hodgkin lymphoma, consider consulting with a hematologist or an oncologist who specializes in lymphomas, particularly those with experience in T-cell malignancies. While no specific patient organizations are identified, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to cutting-edge therapies and contribute to the understanding of this condition.
There are currently three orphan drug designations related to T-cell non-Hodgkin lymphoma, including the FDA-approved drug vorinostat, and two drugs in development: (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride and Tretinoin. Additionally, there are 668 active clinical trials exploring various treatment options and approaches for this condition. For more information, you can search the active trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=T-cell%20non-Hodgkin%20lymphoma.
Actionable guidance for navigating care for T-cell non-Hodgkin lymphoma
To navigate your care for T-cell non-Hodgkin lymphoma, consider consulting with a hematologist or an oncologist who specializes in lymphomas, particularly those with experience in T-cell malignancies. While no specific patient organizations are identified, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to cutting-edge therapies and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding T-cell non-Hodgkin lymphoma is limited primarily due to its relatively low prevalence and the complexity of its clinical presentation. As this condition affects fewer individuals, comprehensive clinical studies have been challenging to conduct. Additionally, the lack of identified genetic factors and systematic characterization of its clinical features contributes to the gaps in available information.
To navigate your care for T-cell non-Hodgkin lymphoma, consider consulting with a hematologist or an oncologist who specializes in lymphomas, particularly those with experience in T-cell malignancies. While no specific patient organizations are identified, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to cutting-edge therapies and contribute to the understanding of this condition.
There are currently three orphan drug designations related to T-cell non-Hodgkin lymphoma, including the FDA-approved drug vorinostat, and two drugs in development: (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride and Tretinoin. Additionally, there are 668 active clinical trials exploring various treatment options and approaches for this condition. For more information, you can search the active trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=T-cell%20non-Hodgkin%20lymphoma.
Actionable guidance for navigating care for T-cell non-Hodgkin lymphoma
To navigate your care for T-cell non-Hodgkin lymphoma, consider consulting with a hematologist or an oncologist who specializes in lymphomas, particularly those with experience in T-cell malignancies. While no specific patient organizations are identified, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to cutting-edge therapies and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 33 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.